Compare CRMT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | ONCY |
|---|---|---|
| Founded | 1981 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 94.0M |
| IPO Year | 2026 | 2002 |
| Metric | CRMT | ONCY |
|---|---|---|
| Price | $11.79 | $1.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $29.50 | $7.33 |
| AVG Volume (30 Days) | 134.8K | ★ 885.3K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $0.33 |
| 52 Week High | $62.55 | $1.51 |
| Indicator | CRMT | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 56.88 |
| Support Level | $11.04 | $0.94 |
| Resistance Level | $13.63 | $1.13 |
| Average True Range (ATR) | 0.85 | 0.09 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 41.07 | 87.53 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.